Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has moved up to the Nasdaq Global Select Market just as its lead clinical program approaches a pivotal Phase 2b interim data event. For many, the timing is rather tidy: the company is pairing greater market…